On June 6, 2019, MiMedx Group, Inc announced that the Board recently collaborated with one of its largest shareholders, Prescience Point Capital Management LLC, to develop a comprehensive Board refreshment plan. MiMedx Group stated that following the 2019 annual meeting, Company’s 10-person Board would include 6 new directors. In addition, the Company stated that it has filed a definitive additional material soliciting proxies and urged the shareholders to vote for the election of its nominees: M. Kathleen Behrens Wilsey, K. Todd Newton, and Timothy R. Wright as directors of the Company at its annual meeting scheduled to be held on June 17, 2019 by voting on its proxy card.
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.